Published in Lab Business Week, July 29th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Barr Pharmaceuticals, Inc.
Report 1: Barr Pharmaceuticals, Inc. (NYSE:BRL) announced that its subsidiary PLIVA has received tentative approval from the U.S. Food and Drug Administration (FDA) for its generic version of Janssen Pharmaceutica Products, L.P.'s Risperdal(R) (Risperidone) Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.
A tentative approval reflects FDA's determination that a generic product satisfies the requirements for final approval, subject to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.